Anti-platelet aggregation

Procurcumenol
Catalog No: CFN92647

Procurcumenol is an inhibitor of Nitric Oxide. Procurcumenol and epicurcumenol have inhibitory effects on release of tumor necrosis factor-a (TNF-a).

Curcolone
Catalog No: CFN92651

Curcolone exhibits inhibition against collagen-induced platelet aggregation at 100 uM, it also inhibit arachidonic acid (AA)-induced platelet aggregation at 100 uM.

Broussoflavonol F
Catalog No: CFN92664

Broussoflavonol F has antiplatelet effect, is partially due to an inhibitory effect on cyclooxygenase, can inhibit arachidonic acid (AA)-induced platelet aggregation. Broussoflavonol F shows inhibitory activities on mushroom tyrosinase. Broussoflavonol F shows radical scavenging against 2,2-diphenyl-1-picrylhydrazyl (DPPH), the IC50 value of 708.54 uM. It also exhibits moderate cytotoxic activities against five human cancer cells with the IC50 value of 0.41-7.2 ug/mL.

Kadsulignan L
Catalog No: CFN92721

Kadsulignan L shows in vitro antiviral effects on hepatitis B virus. It also shows moderate platelet-activating factor (PAF) antagonistic activities with the IC50 value of 2.6 x 10(-5) M.

Loureirin A
Catalog No: CFN92766

Loureirin A has an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling. Loureirin A activates Wnt/-catenin pathway and promotes hair follicle stem cells (FSCs)-seeded tissue-engineered skin to repair skin wound.The molecular mechanism of Loureirin A and Wnt signaling pathway mediated anti- hepatic fibrosis and anti- angiogenesis may involve down- regulation the expression of Frizzled- 4,inhibiting the synthesis and secretion of α- SMA,TGF- β1and the proliferation of HSCs.